EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report

Sho Takuma, MD; Yusuke Inoue, MD, PhD; Masato Karayama, MD, PhD; Kazuo Tsuchiya, MD; Hiroe Tsukui, MD; Hironao Hozumi, MD, PhD; Yuzo Suzuki, MD, PhD; Kazuki Furuhashi, MD, PhD; Noriyuki Enomoto, MD, PhD; Tomoyuki Fujisawa, MD, PhD; Yutaro Nakamura, MD, PhD; Naoki Inui, MD, PhD; Takafumi Suda, MD, PhD

JTO Clinical and Research Reports (Jan 2022)

EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report

Sho Takuma, MD,
Yusuke Inoue, MD, PhD,
Masato Karayama, MD, PhD,
Kazuo Tsuchiya, MD,
Hiroe Tsukui, MD,
Hironao Hozumi, MD, PhD,
Yuzo Suzuki, MD, PhD,
Kazuki Furuhashi, MD, PhD,
Noriyuki Enomoto, MD, PhD,
Tomoyuki Fujisawa, MD, PhD,
Yutaro Nakamura, MD, PhD,
Naoki Inui, MD, PhD,
Takafumi Suda, MD, PhD

Affiliations

Sho Takuma, MD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Yusuke Inoue, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan; Corresponding author. Address for correspondence: Yusuke Inoue, MD, PhD, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan.
Masato Karayama, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Clinical Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan
Kazuo Tsuchiya, MD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Hiroe Tsukui, MD: Department of Diagnostic Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
Hironao Hozumi, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Yuzo Suzuki, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Kazuki Furuhashi, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Noriyuki Enomoto, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Tomoyuki Fujisawa, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Yutaro Nakamura, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
Naoki Inui, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan
Takafumi Suda, MD, PhD: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

Journal volume & issue: Vol. 3, no. 1
p. 100264

Abstract

Read online

Lineage transformation from lung adenocarcinoma (LUAD) to SCLC is associated with resistance to EGFR tyrosine kinase inhibitors. In addition to loss of p53 and RB, transformed SCLCs are usually not dependent on EGFR signaling, which renders the tumors unresponsive to EGFR tyrosine kinase inhibitors. Here, we present a case of spontaneous transformation from EGFR-mutant LUAD with loss of p53 and RB to EGFR expression-positive SCLC and neuroendocrine-differentiated LUAD, which was successfully treated with osimertinib.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords